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ABSTRACT
Background and objective: Nuclear factor kappa B
(NF-kB)-mediated inﬂammatory gene expression and
vascular endothelial cell proliferation/remodelling are
implicated in the pathophysiology of the fatal disease,
pulmonary arterial hypertension (PAH). Bromodomain
and extra-terminal (BET) proteins are essential for the
expression of a subset of NF-kB-induced inﬂammatory
genes. BET mimics including JQ1+ prevent binding of
BETs to acetylated histones and down-regulate the
expression of selected genes.
Methods: The effects of JQ1+ on the proliferation of pri-
mary human pulmonary microvascular endothelial cells
(HPMECs) from healthy subjects were measured by bro-
modeoxyuridine (BrdU) incorporation. Cell cycle pro-
gression was assessed by ﬂow cytometry; mRNA and
protein levels of cyclin-dependent kinases (CDKs), inhibi-
tors and cytokines were determined by reverse
transcription-quantitative PCR (RT-qPCR), Western blot-
ting or ELISA. Histone acetyltransferase (HAT) and dea-
cetylase (HDAC) activities were determined in nuclear
extracts from whole lung of PAH and control patients.
Results: JQ1+ signiﬁcantly inhibited IL6 and IL8 (IL6
and CXCL8) mRNA and protein in HPMECs compared
with its inactive enantiomer JQ1−. JQ1+ decreased NF-
kB p65 recruitment to native IL6 and IL8 promoters.
JQ1+ showed a concentration-dependent decrease in
HPMEC proliferation compared with JQ1−-treated cells.
JQ1+ induced G1 cell cycle arrest by increasing the
expression of the CDK inhibitors (CDKN) 1A (p21cip)
and CDKN2D (p19INK4D) and decreasing that of CDK2,
CDK4 and CDK6. JQ1+ also inhibited serum-stimulated
migration of HPMECs. Finally, HAT activity was signiﬁ-
cantly increased in the lung of PAH patients.
Conclusion: Inhibition of BETs in primary HPMECs
decreases inﬂammation and remodelling. BET proteins
could be a target for future therapies for PAH.
Key words: bromodomain and extra-terminal proteins, human
pulmonary microvascular endothelial cells, inﬂammation, prolif-
eration, pulmonary hypertension.
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SUMMARY AT A GLANCE
Endothelial cell inﬂammation and proliferation are
important in the pathogenesis of pulmonary arterial
hypertension (PAH). Bromodomain and extra-
terminal (BET) mimics reduced inﬂammation and
cell proliferation in primary human pulmonary vas-
cular endothelial cells. The enhanced histone acet-
yltransferase (HAT) activity in PAH lung suggests
that BET mimics may be effective in PAH although
experiments in disease cells/tissues are required.
© 2016 The Authors




Pulmonary arterial hypertension (PAH) describes a
group of diseases characterized by raised pulmonary
vascular resistance, resulting from vascular remodelling
in the pre-capillary resistance arterioles.1 Patients die
from right heart failure within 3 years of diagnosis if
untreated. Treatment with vasodilators, such as
endothelin (ET) receptor antagonists, prostacyclin ana-
logues and phophodiesterase type V inhibitors, has
improved both morbidity and mortality2; however,
these are not a cure and the mortality rate in patients
is still unacceptably high.2 It is, therefore, important to
understand the mechanisms of vascular remodelling in
PAH and to determine novel therapies targeting these
abnormalities.
The endothelial cell plays a key role in vascular
remodelling. Early on in the disease process, increased
apoptosis within the endothelial layer leads to survival
of cells with an apoptosis-resistant phenotype, resulting
in proliferation, which is a hallmark of later disease.3
We and others have shown that pulmonary vascular
endothelial cells in patients with idiopathic PAH
(IPAH) demonstrate markers of increased inﬂamma-
tion, such as nuclear factor kappa B (NF-kB) activa-
tion.4 Moreover, in an in vitro condition, endothelial
cells produce cytokines that are also found circulating
in the plasma of patients with IPAH and correlate with
worse survival.5
Histone acetylation, under the control of histone
acetyltransferases (HATs), is linked to heightened
inﬂammatory gene expression.6,7 Acetylated lysine resi-
dues are removed by histone deacetylases (HDACs).8
Acetylated histones are recognized by bromodomain
and extra-terminal (BET) proteins to enable
co-ordinated regulation of genes involved in cell prolif-
eration, apoptosis and inﬂammation.9,10 Bromodomain-
containing protein (BRD) 4 was signiﬁcantly increased
in PAH lung tissue, distal pulmonary arteries (PAs) and
right ventricle (RV) compared with control tissues. This
over-expression was also demonstrated in isolated PAH
PA smooth muscle cells (PASMCs) compared with con-
trol cells. BRD2 and BRD3 were increased in the distal
PAs from PAH patients compared with controls,
although the difference seen in the BRD3 levels was
not signiﬁcant. In the RV, there was no increase in
BRD2 and only a small increase in BRD3 was
observed.11 Additionally, BRD4 expression was induced
during RV hypertrophy in a rat PAH model.12 The BET
proteins BRD2 and BRD4 are involved in inﬂammatory
gene expression in several murine and human cell
types13–16 and their binding to acetylated histones can
be blocked by molecular mimics such as JQ1+ resulting
in attenuated cell proliferation and differentiation
in vivo and in cell lines.13,17 In an in vivo condition,
BRD4 inhibition using JQ1 or siBRD4 reversed estab-
lished PAH in the Sugen/hypoxia rat model and
decreased proliferation, increased apoptosis and
restored mitochondrial membrane potential in PAH-
PASMCs suggesting that BRD4 up-regulation may be
pathologically associated with PAH in animal models.11
I-BET151, a structurally similar BET mimic, reduces
inﬂammation in in vivo and in vitro conditions follow-
ing LPS challenge.13
The aims of this study were ﬁrst to investigate a role
for BET proteins (using JQ1+) in the regulation of
inﬂammation and markers of vascular remodelling in
human pulmonary microvascular endothelial cells
(HPMECs). Second, to determine the HAT:HDAC ratio
in PAH and control lung tissue to evaluate any poten-




Control specimens (n = 10) were obtained from lung
resected during lobectomy for a solitary pulmonary
nodule. Specimens from patients with IPAH (n = 10)
were obtained following lung transplantation. The
study was approved by the local ethics committee and
all patients gave informed consent (Comité de Protec-
tion des Personnes Ile-de-France, Paris VII). Two to
four randomly selected blocks of lung tissue (size
2 × 2.5 cm) were taken from the sub-pleural paren-
chyma of the lobe obtained at the time of surgery,
avoiding areas of tumour in controls. Nuclear extracts
were isolated (Active Motif, Rixensart, Belgium) and
HAT and HDAC activities determined using commer-
cial assays as previously described.18
Cell culture and treatment
HPMECs from healthy subjects (PromoCell GmbH,
Heidelberg, Germany) were grown in EGM2 medium
and passaged using the Detach subculture kit
(PromoCell GmbH) following the manufacturer’s
instructions. Cells were cultured until 70% conﬂuent at
37C and 5% CO2. Twenty-four hours prior to experi-
ments, media was changed to EGM2 containing 0.1%
foetal calf serum (FCS) before being returned to media
containing 5% FCS in the presence or absence of the
BET mimic JQ1+ or its inactive enantiomer JQ1−. Cells
were used at passages 4–8 and all experiments
repeated at least four times.
Measurement of mRNA transcripts
Total RNA was isolated using RNeasy mini kit (Qiagen,
Crawley, UK). Single-stranded cDNA was synthesized
using oligo(dT)12–18 primer and MMLV-reverse tran-
scriptase (Life Technology, Paisley, UK). Quantitative
PCR (qPCR) was performed in a Rotor-Gene 6000 PCR
machine (Corbett Research, Cambridge, UK) using a
QuantiTect SYBR Green PCR kit and QuantiTect pri-
mers (Qiagen). PCR data for each gene was normalized
to a housekeeping gene, β-actin and represented as
fold change respective to the t = 0 time point, using the
delta–delta CT (2−ΔΔCT) method.19
Enzyme-linked immunosorbent assays
CXCL8 (IL8 protein), epidermal growth factor (EGF),
ﬁbroblast growth factor (FGF) and ET-1 in culture
supernatants were analysed by sandwich ELISA (R&D
Systems, Oxford, UK). IL6 levels were determined by
high sensitivity ELISA (eBioscience Ltd, Hatﬁeld, UK).
© 2016 The Authors
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ChIP assay
Chromatin immunoprecipitation (ChIP) assay was car-
ried out using EZ-ChIP kit (Millipore, Watford, UK)
according to the manufacturer’s protocol. Cells were
treated with JQ1 (1 μmol/L) for 3 h and formaldehyde
(1% ﬁnal concentration) was added to ﬁx the protein–
DNA complexes. Cells were sonicated to shear the
DNA into 100–1000 bp fragments. Immunoprecipita-
tion was carried out overnight with an anti-p65 anti-
body (5 μg, Santa Cruz Biotechnology, Santa Cruz, CA,
USA). NF-kB p65 binding to the IL8 and IL6 promoter
was quantiﬁed by real-time qPCR, using SYBR Green
on a Rotor-Gene 6000 (Corbett Research). The fold
change was calculated as (2−(Ct(input)−Ct(ChIP))) com-
pared with the IgG negative control. Primer pairs of IL6
and IL8 were as follows: IL6, forward, 50-AGCACTGG-
CAGCACAAGGCAAAC-30 and IL6, reverse,
50-CAAGCCTGGG-ATTATGAAGAAGG-30; and IL8,
forward, 50-GGGCCATCAGTTGCAAATC-30 and IL8,
reverse, 50-TTCCTTCCGGTGGTTTCTTC-30.
Cell viability and proliferation
Cell viability was analysed by quantiﬁcation of mito-
chondrial reduction of MTT (3-(4,5-dimethyl-2 thiazo-
lyl)-2-5-diphenyltetrazolium bromide) to formazan.
HPMEC proliferation was assessed by measuring the
incorporation of bromodeoxyuridine (BrdU) using a
cell proliferation ELISA (Roche Diagnostics, Burgess
Hill, UK).
Flow cytometry
FACS analysis was used to measure cell cycle progres-
sion. After treatment with JQ1 for 24 h, cells were har-
vested, spun down at 4C and washed before being
ﬁxed with 70% ethanol. RNA was degraded with RNAase
and DNA stained with propidium iodide. Samples were
analysed on a BD FACS Canto II (BD Biosciences,
Oxford, UK). Histograms were generated and cell cycle
analysis was performed using FlowJo cytometry analysis
software (FlowJo, LLC, Ashland, OR, USA).
Western blotting
HPMECs were harvested on ice and proteins isolated
for Western blotting as previously described.20 Protein
content was determined using the Bradford protein
assay (Bio-Rad Laboratories Ltd, Hemel Hempstead,
UK). Blots were probed for either cyclin-dependent
kinase (CDK) inhibitor (CDKN) 1A (p21cip) or the load-
ing control β-actin (New England Biolabs (UK) Ltd,
Hitchin, UK) and detected using a horseradish
peroxidase-linked anti-rabbit immunoglobulin (New
England Biolabs) and enhanced chemiluminescence
(GE Healthcare, Amersham, UK).
Cell migration
HPMECs were added to the upper chamber of a 24-
well insert (8 mm pore, TranswellH, VWR International
Ltd, Lutterworth, Leicestershire, UK) in the presence of
JQ1 (1 μmol/L) either added immediately or pre-
incubated for 90 min. Medium (600 μL) containing 0%
(negative control) or 5% FCS was added to the lower
chamber. After 4 h, cells in the upper chambers were
removed with cotton buds. If cells were left for >4 h,
they had moved entirely through the membrane and
into the lower chamber. Cells on the lower chamber
membranes were ﬁxed with 3.7% formaldehyde for
5 min, membrane was then cut and mounted between
a slide and a cover slip in ProLong antifade mounting
solution containing DAPI (Invitrogen, Paisley, UK).
Images were taken using a Zeiss Fluorescence micro-
scope (Carl Zeiss Ltd, Cambridge, UK).
Statistical analysis
Data are represented as mean  SEM. Data were ana-
lysed by Student’s t-test for two groups of data, by one-
way analysis of variance (ANOVA)/Dunn’s multiple
comparison test for more than two data sets or by area
under the curve (AUC) using GraphPad Prism
(GraphPad Prism Software, La Jolla, CA, USA). Differ-
ences were considered signiﬁcant for P < 0.05.
RESULTS
JQ1 inhibits IL6 and IL8 expression
JQ1+ (1 μmol/L) decreased IL6 mRNA at 4, 8 and 24 h
and IL8 mRNA at 4 h compared with JQ1-treated cells
(Fig. 1A,B). At 24 h, JQ1+ signiﬁcantly inhibited the
release of IL6 and CXCL8 from HPMECs (Fig. 1C,D).
JQ1+ had no signiﬁcant effect on the basal release of
EGF, FGF or ET-1 (data not shown). Cell viability was
not affected by JQ1+ or JQ1− at 0–1000 nmol/L.
JQ1 prevents recruitment of NF-kB p65 to
native IL6 and IL8 promoters
We used ChIP analysis to investigate the effect of JQ1
on the recruitment of NF-kB p65 to the IL6 and IL8
promoters. JQ1+ (1 μmol/L) signiﬁcantly reduced bind-
ing of p65 to the IL6 promoter by 50% compared with
the sixfold enrichment seen in JQ1-treated cells
(Fig. 1E). JQ1+ had a similar effect on p65 recruitment
to the IL8 promoter (Fig. 1F).
JQ1 inhibits proliferation
JQ1+ signiﬁcantly decreased serum-stimulated prolif-
eration of HPMECs in a concentration-dependent
manner after 24 h. In contrast, there was no effect of
JQ1− on serum-stimulated proliferation (Fig. 2).
JQ1 prevents cell cycle progression
JQ1+, but not JQ1−, signiﬁcantly increased the percent-
age of HPMECs in G0/G1 and decreased the percent-
age of cells in G2/M following serum stimulation
(Table 1, Fig. S1 (Supplementary Information)). JQ1+
signiﬁcantly enhanced CDKN1A (p21cip) mRNA expres-
sion after 4 h which was not seen with JQ1− (Fig. 3A).
The increase in CDKN1A mRNA was mirrored by a sig-
niﬁcant increase in protein expression at 24 h
(Fig. 3B,C).
JQ1+ also signiﬁcantly increased CDKN2D (p19INK4D)
mRNA expression compared to JQ1− (Fig. 4A) and
Respirology (2016) © 2016 The Authors
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signiﬁcantly decreased CDKN2A (p16INK4A) (Fig. 4B).
No change in the mRNA levels of CDKN1B (p27kip1) or
CDKN2B (p15INK4B) was observed (Fig. S2, Supplemen-
tary Information). JQ1+ also reduced CDK2, CDK4 and
CDK6 mRNA levels compared with cells treated with
JQ1− but this only reached signiﬁcance for CDK4
(Fig. 4C–E).
JQ1+ inhibits HPMEC migration
JQ1+ (1 μmol/L) caused a signiﬁcant decrease in
serum-stimulated endothelial cell migration compared
with JQ1− after 4 h (Figs 5, S3 (Supplementary
Information)). Pre-treatment of HPMECs with JQ1+
produced a similar level of suppression of migration
compared with that seen when JQ1+ was added at the
same time as the stimulus.
Disrupted HAT activity in IPAH lung
Lung tissue from IPAH patients showed signiﬁcantly
decreased nuclear HDAC and increased nuclear HAT
activity compared with non-PAH lung tissue (Fig. 6A,
B). This resulted in a higher HAT:HDAC ratio in IPAH
lung tissue compared with non-PAH tissue samples
(Fig. 6C).
Figure 1 JQ1+ decreases the expression
of serum-stimulated IL6 and IL8 mRNA
and protein and decreases recruitment of
nuclear factor kappa B (NF-kB) p65 to IL6
and IL8 promoters in human pulmonary
microvascular endothelial cell (HPMEC).
Vascular endothelial cells were treated
with media (5% foetal calf serum (FCS))
with 1 μmol/L JQ1+ (black circles) or
JQ1− (white circles) for 0–24 h. Relative
levels of IL6 (A) and IL8 (B) mRNA and
IL6 (C) and IL8 protein (CXCL8)
(D) release were measured. Chromatin
immunoprecipitation (ChIP) analysis of
NF-kB p65 binding to the IL6 (E) and IL8
(F) promoters was quantiﬁed by reverse
transcription-quantitative PCR (RT-qPCR).
*P < 0.05, **P < 0.01 and ***P < 0.001
when JQ1+ was compared with JQ1−.
Figure 2 JQ1 decreases serum-
stimulated proliferation in human
pulmonary microvascular endothelial cell
(HPMEC). Cells were incubated with
media containing 0.1% or 5% foetal calf
serum (FCS) (Bars) and with 5% FCS
media with either JQ1+ (black circles) or
JQ1− (white circles) at the stated
concentrations for 24 h. Cell proliferation
was measured. **P < 0.01 and
***P < 0.001 comparing JQ1+ and JQ1
−-treated cells.
© 2016 The Authors
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DISCUSSION
The BET mimetic JQ1+, but not its inactive enantiomer,
JQ1−, decreased IL6 and IL8 mRNA and protein expres-
sion from HPMECs, which was associated with reduced
p65 recruitment to the native IL6 and IL8 promoters. JQ1
+ also decreased serum-stimulated proliferation of
HPMECs. JQ1+ caused cell cycle arrest at G1 linked to
increased expression of the cell cycle inhibitors CDKN1A
(p21cip) and CDKN2D (p19INK4D) together with reduced
CDK2, CDK4 and CDK6 expression. Furthermore, JQ1+
inhibited serum-stimulated migration of HPMECs.
Finally, we demonstrated that there is increased HAT
and reduced HDAC activity in IPAH lung.
The pulmonary endothelium controls vasodilator/
constrictor balance as well as vascular permeability
and regulates the local balance between pro- and anti-
inﬂammatory mediators, anti-coagulant and anti-
adhesive properties and cell proliferation.21 Vasomotor
tone is controlled by the balance between vasodilators
such as nitric oxide and prostacyclin and vasoconstric-
tors such as ET-1.21 This balance is lost in PAH patients
with increased ET-1 release and reduced nitric oxide
and prostacyclin production and current therapies are
aimed at countering this imbalance. However, these
therapies do not treat the other hallmark of PAH; pul-
monary vascular remodelling.
A key event in PAH is NF-kB activation within the vas-
cular endothelium of IPAH lung. These endothelial cells
release NF-kB-regulated cytokines and chemokines,
including IL6, IL8 and MCP-1 whose expression are
increased in the plasma of patients with IPAH and is
predictive of clinical outcome.5,22 Novel agents are
required that target these abnormalities. The only drug
to date to target remodelling per se is the PDGF receptor
kinase inhibitor, imatanib, which reduced pulmonary
vascular resistance in patients with severe PAH but its
use was associated with intolerable side effects.23,24 We
show that the BET mimetic, JQ1+ (which has a higher
afﬁnity for BRD4 than other Brds25), inhibits key inﬂam-
matory processes in human primary HPMECs. Further
studies in patient cells will determine which BET pro-
teins may be important in PAH pathogenesis.
Serum stimulates HPMEC proliferation through mul-
tiple potential pathways, including, the production of
IL6 and causes endothelial cell migration.26 In this
study, we show for the ﬁrst time that JQ1+ inhibits
serum-stimulated proliferation and migration of
HPMECs. Furthermore, we demonstrated that JQ1
Figure 3 JQ1+ increases cyclin-dependent kinase inhibitor
CDKN1A in human pulmonary microvascular endothelial cell
(HPMEC). Vascular endothelial cells were treated with media
(5% foetal calf serum (FCS)) containing either 1 μmol/L JQ1+ or
JQ1− for (A) 0–24 h and mRNA levels of CDKN1A determined
relative to β-actin by real-time quantitative PCR (qPCR). (B) A
representative Western blot of CDKN1A showing β-actin as the
loading control. (C) Densitometric analysis of n = 4 independent
experiments. *P < 0.05 when JQ1+ was compared with JQ1−.
Table 1 Effect of JQ1 on cell cycle progression (ﬂow cytometry analysis) in human pulmonary microvascular
endothelial cell (HPMEC)
Concentration G0/G1 phase S phase G2/M phase
10 nmol/L JQ1− 76.27  0.96 3.97  0.37 18.74  0.94
JQ1+ 76.43  0.85 4.03  0.33 18.29  0.73
100 nmol/L JQ1− 75.57  1.04 4.23  0.49 18.83  0.80
JQ1+ 75.99  1.18 3.76  0.26 18.84  0.88
500 nmol/L JQ1− 76.26  0.91 3.88  0.26 18.57  0.91
JQ1+ 78.84  1.58 2.57  0.35 17.10  1.05
1000 nmol/L JQ1− 75.74  1.05 4.05  0.33 19.09  1.09
JQ1+ 82.14  0.86*** 1.38  0.05 15.41  0.88*
Cells were treated with 0-1000nmol/L JQ1(+) or JQ1(−) in full media for 24 h. Samples were analysed on a BD FACS Canto II and his-
tograms generated and cell cycle analysis performed using FlowJo. Data are mean  SEM, n = 6, *P < 0.05, ***P < 0.001, when com-
pared with the same concentration of inactive JQ1.
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increased CDKN1A and CDKN2D levels which was
associated with increased G0/G1 arrest. Interestingly,
CDKN1A levels were decreased in a rodent model of
PAH27 and JQ1 increased CDKN1A protein expression
in PAH-PASMCs within 16 h of treatment showing
rapid arrest of proliferation by BRD4 inhibition.11 Previ-
ous studies have shown that JQ1 inhibited proliferation
and differentiation of mouse cancers in vivo and of a
number of other cell lines in vitro.17 This suggests a
potential anti-remodelling effect of JQ1+ by BRD4 inhi-
bition in pulmonary microvascular endothelial cells.
In this study, we only used serum as the stimulus for
cytokine production and in future studies it would be
important to investigate whether JQ1+ can attenuate
proliferation and remodelling induced by other stimuli
such as shear stress, hypoxia and cytokines as well as
comparing responses to cells derived from patients
with PAH and in other cell types such as smooth mus-
cle cells and ﬁbroblasts. The effect of JQ1+ in an animal
model of PAH may further elucidate the potential of
this class of drugs for the treatment of the disease.
The HAT:HDAC activity ratio was signiﬁcantly
altered in whole lung tissue of IPAH patients.
Although we do not provide evidence of cellular spec-
iﬁcity, it does suggest that altered acetylated histone
states could be important in the development of
human PAH. The relative protein or mRNA expression
of BET isoforms in HPMECs in healthy patients or in
disease is unknown. However, BRD4 is increased in
PAH lung tissue, distal PAs, RV and isolated PASMCs
compared with control tissues and cells. Levels of
BRD2 and BRD3 are increased in the distal PAs from
PAH patients compared with controls, although the
difference in BRD3 levels was not signiﬁcant. In the
RV, no increase in BRD2 and only a small increase in
BRD3 were observed.11 Enhanced BRD4 expression
was also induced during RV hypertrophy in a rat PAH
Figure 4 Effect of JQ1 on human
pulmonary microvascular endothelial cell
(HPMEC) cell cycle genes involved in G1
to S phase progression. Cells were treated
with media (5% foetal calf serum (FCS))
containing either 1 μmol/L JQ1+ (black
circles) or JQ1− (white circles) for 0–24 h
and relative mRNA levels of cyclin-
dependent kinase (CDK) inhibitors (A,B)
and CDKs (C–E) are shown. *P < 0.008
when the area under the curve for JQ1+
was compared with JQ1−.
Figure 5 JQ1+ decreases serum-stimulated migration of
human pulmonary microvascular endothelial cell (HPMEC).
HPMECs were seeded onto transwell inserts and cell migration
was measured. Migrated cells, under the conditions described,
were counted and expressed graphically, as the percentage of
the control. Data are presented as mean  SEM. *P < 0.05
and **P < 0.01.
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model.12 BRD4 mRNA is expressed at 10 times the
level of BRD2 and BRD3 in cardiomyocytes and pro-
phylactic JQ1 treatment is effective at counteracting
the effect of two different inducers of left ventricular
heart failure particularly in relation to the inﬂamma-
tory drive.28 This provides an excellent rationale for
the extension into therapeutic interventions in a
mouse model of PAH. Indeed, non-speciﬁc histone
acetylation modiﬁers reverse the development of PAH
and both right and left ventricular function in several
animal models.29–31
There are a number of BRD proteins that perform cell-
speciﬁc roles. BRD2 has an anti-inﬂammatory role in
murine macrophages by targeting acetylated p65,14
whereas BRD4, but not BRD2, has an anti-inﬂammatory
effect in primary human airway structural cells inde-
pendent of p65 acetylation.32 Our study does not deﬁne
the precise mechanism or role of individual BET proteins
in regulating inﬂammation in pulmonary vascular endo-
thelial cells. However, we have shown that the BET
mimic JQ1+ has potentially important anti-inﬂammatory
and anti-remodelling effects on HPMECs which could be
of relevance to the pathogenesis of PAH. Further work
using JQ1+, or similar drugs, is necessary in cells from
PAH patients and in relevant in vivo models.
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Figure S1 JQ1+ decreases cell cycle progression.
Figure S2 Effect of JQ1 on human pulmonary microvascular
endothelial cell (HPMEC) cycle genes involved in G1 to S phase
progression.
Figure S3 JQ1+ decreases serum-stimulated migration of human
pulmonary microvascular endothelial cell (HPMEC). HPMECs
were seeded onto transwell inserts and cell migration measured.
Representative images of cells from three independent experi-
ments (nuclei identiﬁed with DAPI staining) migrated to the
lower chamber are shown.
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